Recently Featured

Biopharma Industry Confidence at Highest in Years Despite Geopolitical Headwinds

June 26, 2026
According to GlobalData, the biopharma industry is experiencing its highest level of confidence in years, even as geopolitical tensions continue to pose challenges. This resilience is underscored by a significant uptick in mergers and acquisitions (M&A), which serves as a clear indicator of recovery and growth within the sector. The ability of companies to navigate…

Biogen to acquire RayThera for up to $1bn

June 26, 2026
Biogen is set to acquire RayThera, a biotechnology firm focused on developing small-molecule therapies for immunology, in a deal valued at up to $1 billion. This acquisition marks a significant move for Biogen, as it seeks to enhance its pipeline in the immunology space, an area of increasing importance in the pharmaceutical industry. The context…

Voro and Alloy Partner on Tumour-Selective TCE Therapeutics

June 26, 2026
Voro Therapeutics and Alloy Therapeutics have announced a strategic research partnership aimed at developing tumour-selective, next-generation masked T cell engagers (TCEs). This collaboration represents a significant advancement in the field of targeted cancer therapies, as it seeks to enhance the specificity and efficacy of TCEs while minimizing off-target effects. By leveraging Alloy’s proprietary platform and…

Update on the PATHWAYS Clinical Trial

June 25, 2026
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has provided a crucial update regarding the PATHWAYS clinical trial, emphasizing its unwavering commitment to participant safety. This trial, which explores innovative treatment pathways, has undergone rigorous scrutiny to ensure compliance with safety protocols. The MHRA’s proactive approach reflects broader regulatory trends aimed at enhancing patient…

Ongoing Cases